Koppel to leave Biogen

Biogen Inc. (NASDAQ:BIIB) said EVP of Strategy and Business Development Adam Koppel will leave the company on June 2. He had led the biotech's business development activities since EVP of Corporate Development Steven Holtzman retired in March.

CEO George Scangos is to take over Koppel's corporate strategy duties, Biogen said. Newly hired EVP of R&D Michael Ehlers will assume Koppel's business development responsibilities, and EVP and CFO Paul Clancy will assume his M&A duties. Spokesperson Mark Dole said Biogen does not plan to fill Koppel's role. ...